ESPERION | REACHING GOALS

Q1 2023 Earnings Presentation

May 9, 2023

Forward-looking Statements & Disclosures

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the impact of the ongoing COVID-19 pandemic on our business, revenues, results of operations and financial condition, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes of legal proceedings, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Business Overview

Sheldon Koenig, President and CEO

Strong Q1 2023 Growth

$24M

Total Revenue
+29% Y/Y

$17M

US Product Sales, Net
+27% Y/Y

+15%

Retail Prescription Equivalents Y/Y

Q1 2023 and Recent Highlights

- Reported positive primary and secondary endpoints from the **CLEAR Outcomes trial in March 2023 at ACC and in the *New England Journal of Medicine*** showing robust CV risk reduction, including >20% reduction in fatal and non-fatal MI
- On track for **regulatory submissions to FDA and EMA** in 1H 2023
- **New-to-Brand Prescriptions Grew 56% Q/Q**
- International Lipid Expert Panel (ILEP) recommended use of **bempedoic acid ahead of PCSK9 inhibitors** in managing lipid disorders and cardiovascular risk
- The **Italian Medicines Agency (AIFA) approved reimbursement** of bempedoic acid and the fixed-dose combination of bempedoic acid and ezetimibe, and marketing approval was also obtained in **Turkey**
- Launched new scientific website, **esperionscience.com**, designed specifically for the scientific and medical communities
- Announced a pay-for-performance commercial partnership with Currax Pharmaceuticals, LLC that **doubles promotional footprint**

Continued Coverage *New England Journal of Medicine* Publication



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

S.E. Nissen, A.M. Lincoff, D. Brennan, K.K. Ray, D. Mason, J.J.P. Kastelein, P.D. Thompson, P. Libby, L. Cho, J. Plutzky, H.E. Bays, P.M. Moriarty, V. Menon, D.E. Grobbee, M.J. Louie, C.-F. Chen, N. Li, L.A. Bloedon, P. Robinson, M. Horner, W.J. Sasiela, J. McCluskey, D. Davey, P. Fajardo-Campos, P. Petrovic, J. Fedacko, W. Zmuda, Y. Lukyanov, and S.J. Nicholls, for the CLEAR Outcomes Investigators*

ABSTRACT

BACKGROUND

Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain.



NEJM
@NEJM

CLEAR Outcomes trial: Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events. Full trial results: nej.md/3kws1T6

Editorial: Benefits of Bempedoic Acid — Clearer Now
nej.md/3IZU7iV pic.twitter.com/GKuQykciCZ
4/12/23, 5:20 PM



The NEW ENGLAND JOURNAL of MEDICINE

RESEARCH SUMMARY

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen SE et al. DOI: 10.1056/NEJMoa2215024

CLINICAL PROBLEM

Bempedoic acid is an ATP citrate lyase inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels without the elevated risk of musculoskeletal adverse effects associated with statins. Although the goal of reducing LDL cholesterol levels is to prevent adverse cardiovascular events, studies of the effects of bempedoic acid on cardiovascular events are lacking.

CLINICAL TRIAL

Design: An international, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of bempedoic acid for the prevention of adverse cardiovascular events in statin-intolerant patients.

Intervention: 13,970 patients 18 to 85 years of age at increased cardiovascular risk who were unable or unwilling to take guideline-recommended doses of statins were assigned to receive 180 mg of oral bempedoic acid or placebo daily. The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization.

RESULTS

Efficacy: After a median follow-up of 40.6 months, the incidence of major adverse cardiovascular events was significantly lower in the bempedoic acid group than in the placebo group.

Safety: The incidences of adverse events were similar in the two groups overall; however, the bempedoic acid group had higher incidences of elevated hepatic enzymes, renal impairment, hyperuricemia, gout, and cholelithiasis.

LIMITATIONS AND REMAINING QUESTIONS

- The trial included only patients who were unable or unwilling to take statins, and therefore the mean LDL cholesterol level was high at baseline. The findings cannot be generalized to populations with lower LDL cholesterol levels.

Links: Full Article | NEJM Quick Take | Editorial | Science behind the Study

Four-Component Composite of Major Adverse Cardiovascular Events

HR, 0.87 (95% CI, 0.79–0.96); P=0.004

Adverse Events

	Bempedoic acid (N=7001)	Placebo (N=6964)
	no. of patients (%)	
Any adverse event	6040 (86.3)	5919 (85.0)
Elevated hepatic enzymes	317 (4.5)	209 (3.0)
Renal impairment	802 (11.5)	599 (8.6)
Hyperuricemia	763 (10.9)	393 (5.6)
Gout	215 (3.1)	143 (2.1)
Cholelithiasis	152 (2.2)	81 (1.2)

CONCLUSIONS

Among patients at increased cardiovascular risk who were unable or unwilling to take statins, treatment with bempedoic acid significantly reduced the risk of major adverse cardiovascular events.

ACC U.S. CLEAR Coverage: (Print, TV, Radio & Healthcare Trades)

97 print & trade articles

426 broadcast mentions

1.27B+ impressions

Commercial Update

Eric Warren, Chief Commerical Officer

NBRX Growth Further Accelerated Post ACC

Q1 growth +56% Q/Q; post-ACC growth +88% Q/Q

Franchise New to Brand Rx Trends



Enhanced Positioning Following CLEAR Outcomes

Substantial Increase in Addressable Patients by Removing Max-Tolerated Statin and ASCVD Limitations

Today

"ADD" NEXLETOL/NEXLIZET to reduce LDL-C

Post CLEAR Outcomes Label Update

NEXLETOL/NEXLIZET is the CLEAR Next Step after statins, as it is the first non-statin LDL-C lowering therapy to demonstrate outcomes benefit in a combination of High-Risk Primary and Secondary Prevention Patients

Data Drive Meaningful Label Expansion Potential

Driving future commercial growth opportunity

Before

INDICATION:

- Adjunct to diet and maximally tolerated statin therapy
- For the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C

LIMITATIONS:

- Cardiovascular morbidity and mortality effect has not been determined

Positive CVOT

After

POTENTIAL LABEL IMPLICATIONS:

- Additional indication: REDUCE THE RISK OF CARDIOVASCULAR EVENTS
- Post CVOT Potential Label Modifications:
  - Removes maximally tolerated statin therapy
  - Expands to primary and secondary prevention

CLEAR Outcomes

H1 2023
Planned sNDA Submission
Planned EMA Submission

H2 2023
Scientific & Medical Meeting Presentations

H1 2024
Potential CV Risk Reduction Label Inclusion - U.S. and Europe

Commercial Activities To Position NEXLETOL and NEXLIZET as the CLEAR Next-Step after Statins

Completed in Q1 2023

HCP Segmentation and Field Sales Force Sizing

Starting in Q2 2023

Enhanced Digital Outreach Aligned with HCP Segmentation

Wave 1 Sales Force Expansion

Partnership w/Currax to Expand PCP Reach by 72 reps (2x)

Expected to Start in Q3 2023



Prepare CLEAR Launch Campaign and Promotional Messaging

Targeted Consumer Activation

Expected to Start in Q4 2023

Wave 2 Sales Force Expansion

Financial Update

Ben Halladay, Chief Financial Officer

Q1 2023 U.S Net Revenue of $17.0 Million

+27% U.S. net revenue growth Y/Y, with +15% TRPE growth Y/Y

Quarterly Franchise RPE Trend



Weekly Franchise RPE Trend [1]



1. Through March 31, 2023. Weekly trends include 2021, 2022, and 2023.
Based on Symphony Data. RPE = Retail Prescription Equivalent; derived by normalizing the extended Rx units (number of tablets) to determine the 30-day supply equivalent.

EU Patients on Nilemdo®/Nustendi®



~97,000 pts
through Feb ‘23

Note: Numbers are approximate and based on an internal calculation methodology and includes Germany, UK, Austria, Belgium, and Switzerland.

Strong Capital Position Enables Growth

Recent capital raise plus prudent expense management extends cash runway

$162M Q1 2023 Cash, Cash Equivalents & Investment Securities Available-for-Sale

$300M Milestone for European Label Expansion

$140M Milestone for Japanese Submissions & Regulatory Events

$17M Q1 2023 U.S. Net Product Revenue
+27% Growth Y/Y

Key Financial Data

FY 2023 R&D Guidance	$100 - 110 Million
FY 2023 SG&A Guidance	$125 - 135 Million
FY 2023 Op Ex Guidance[1]	$225 - 245 Million
Q1 2023 Common Shares Outstanding [2]	87.2 Million

1. Includes $25M of non-cash stock-based compensation expense
2. After accounting for 2.0 million treasury shares to be purchased in the $50M prepaid forward transaction as part of the November 2020 convertible debt financing

Corporate Update

Sheldon Koenig, President & CEO

Corporate Update

- Raised $56 million in follow-on offering on March 22, extending cash runway
- Announced annual shareholder meeting will be held on May 25
- Filed amended complaint against European commercial partner on May 4

After a Statin, NEXLETOL and NEXLIZET are Next!

1

Robustness of CLEAR Outcomes data has driven awareness on a global scale of the important CV benefits of NEXLETOL and NEXLIZET, leading to wide acceptance by providers, patients and payers. We anticipate filing shortly for broad CV risk reduction label. Additional important presentations and sub-analyses planned at upcoming congresses and in top tier journals.

2

We anticipate significant increases across key metrics, including: NRPE, TRPE and NBRX post ACC / simultaneous publication of CLEAR Outcomes validate the clinical significance of these data. Label change and full-scale promotion is expected to unlock full, blockbuster potential of NEXLETOL and NEXLIZET.

3

Based on the robustness of the CLEAR Outcomes data, the Company believes it would be entitled to receive milestone payments from collaborative partners upon inclusion of cardiovascular risk reduction data in the US and European labels[1].

1. As previously disclosed, the Company has filed a complaint seeking a judicial declaration that our European commercial partner is contractually required to make a $300 million milestone payment.

Q & A

THANK YOU

ESPERION | REACHING GOALS

Important Safety Information

NEXLETOL® Safety Profile

- Contraindications: None
- Warnings and Precautions:
  - Hyperuricemia: NEXLETOL may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day) due to increased risk of adverse events.
- Most common adverse reactions in ≥2% of patients taking NEXLETOL and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

This summary does not reflect the full safety profile – please see https://pi.esperion.com/nexletol/nexletol-pi.pdf

NEXLIZET® Safety Profile

- Contraindication: Known hypersensitivity to ezetimibe tablets
- Warnings and Precautions:
  - Hyperuricemia: Bempedoic acid may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: Bempedoic acid is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day). Monitor cyclosporine concentrations with cyclosporine. If cholelithiasis is suspected in a patient receiving fenofibrate, consider alternative lipid-lowering therapy.
- Most common adverse reactions in >2% of patients taking NEXLIZET and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes, diarrhea, fatigue, influenza, sinusitis, and arthralgia
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

This summary does not reflect the full safety profile - see https://pi.esperion.com/nexlizet/nexlizet-pi.pdf

References

1. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Sep 10;74(10):1376-1414. doi: 10.1016/j.jacc.2019.03.009. Epub 2019 Mar 17. Erratum in: J Am Coll Cardiol. 2019 Sep 10;74(10):1428-1429. Erratum in: J Am Coll Cardiol. 2020 Feb 25;75(7):840. PMID: 30894319; PMCID: PMC8344373.

2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625.

3. Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes. A cohort study. Ann Intern Med. 2017. [Epub ahead of print]. doi:10.7326/M16-0838

4. Serban M-C, Colantonio LD, Manthripragada AD, et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol. 2017;69(11):1386-1395.

5. Stroes ES, Thompson PD, Corsini A, et al; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 1;36(17):1012-22. doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18. PMID: 25694464; PMCID: PMC4416140.

6. Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361-375. doi:10.1016/j.jacl.2022.05.068. Epub 2022 Jun 9.

7. Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 2016; 7: 13457.

8. Ray KK, Bays HE, Catapano AL, et al. CLEAR Harmony Trial. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019 Mar 14;380(11):1022-1032. doi: 10.1056/NEJMoa1803917. PMID: 30865796.